SCHEMBL16149341

SCHEMBL16149341

COc1ccc(NC(=O)c2ccc(OC)cc2OC)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.74
RAB9A P51151 10/20 0.74
KMT2A Q03164 5/20 0.74
MEN1 O00255 4/20 0.74
ALDH1A1 P00352 2/20 0.65
SMN1; SMN2 Q16637 4/20 0.63
KDM4E B2RXH2 1/20 0.63
LMNA P02545 1/20 0.63
HDAC8 Q9BY41 1/20 0.62
CYP2C9 P11712 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
TP53 P04637 3/20 0.60
ALOX15 P16050 1/20 0.60
MITF O75030 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
HPGD P15428 1/20 0.59
CASP3 P42574 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16148074 0.92 NPC1 (0.69) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL4141992 0.91 KMT2A (0.75) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL30786728 0.91 KMT2A (0.75) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL14157012 0.90 NPC1 (0.66) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL29627549 0.89 KMT2A (0.73) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL25383722 0.88 NPC1 (0.64) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL4939367 0.86 KMT2A (0.69) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL16147837 0.85 TP53 (0.61) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2229876 0.84 NPC1 (0.59) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL3949532 0.84 KMT2A (0.78) NPC1RAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160068542-A1 Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2016-03-10 US claimed
EP-2981530-A2 ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS The Administrators of the Tulane Educational Fund (US) 2016-02-10 EP claimed
WO-2014165723-A2 ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2014-10-09 WO claimed
EP-2981530-B1 ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2020-02-12 EP disclosed
US-20160068542-A1 Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2016-03-10 US disclosed
US-20160068542-A1 Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2016-03-10 US disclosed
EP-2981530-A2 ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS The Administrators of the Tulane Educational Fund (US) 2016-02-10 EP disclosed
WO-2014165723-A2 ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068542-A1 Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells HPGDS, CXCL12, ALPG NPC1 4308/4885RAB9A 1653/4885KMT2A 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.